Transthyretin amyloid cardiomyopathy, also known as ATTR-CM in short, is a heart muscle disorder that often goes undetected and can be life-threatening. In ATTR-CM, a protein called transthyretin, typically found in the bloodstream, becomes abnormal in shape and accumulates in the heart, nerves, and other organs. Worldwide, there are an estimated 300,000 - 500,000 patients with ATTR-CM. Pfizer's Vyndaqel and Vyndamax capsules are the FDA-approved treatments for ATTR-CM.
The stock we are bringing to your attention today is that of BridgeBio Pharma Inc. (BBIO) whose investigational drug for the treatment of transthyretin amyloid cardiomyopathy is at the FDA altar, awaiting a decision.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com